Expert Insights’ Post

STATE OF THE STERILE FILL-FINISH MARKET 2024 REPORT. The most up to date data and analysis of markets, pipelines, trends and outsourcing details on the Sterile Fill-Finish Market, with exclusive insights from C-Level operating executives on context and implications. Published by Expert Insights, the World's Leading Advisory Services, Investment Research and Strategy Consulting Firm in Pharma Services. SAMPLE OF PHARMA & BIOTECHS COVERED AND MENTIONED: AbbVie, Amgen, AstraZeneca, Baxter International, Bayer AG, BioNTech, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, Endo Pharmaceutical, F. Hoffmann-La Roche, Gilead Sciences, GSK, Johnson and Johnson, Merck & Co, Moderna, Novartis, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceutical, Teva Pharmaceutical SAMPLE OF CDMOs COVERED AND MENTIONED: Aenova, AGC Biologics, Ajinomoto, Alcami, Almac, Argonaut Manufacturing Services, August Bioservices, Bora Pharma Co, Bushu Pharma, Carbogen Amcis, Catalent Pharma Solutions, Curia, Delpharm, Fareva, Fujifilm Diosynth, Grand River Aseptic Manufacturing, INCOG, Jubilant HollisterStier, Lifecore Biomedical, Lonza, National Resilience, Northway Biotech, PCI Pharma, Pii, Recipharm, Samsung Biologics, Selkirk Pharma, Sharp Packaging, Siegfried Holdings, Simtra BioPharma Solutions, Singota Solutions, ten23 Health, ThermoFisher Patheon, Vetter, Wuxi STA, And many others. The report will be invaluable to CDMO investors, dealmakers and market, strategy, sales, and Research & Development executives, including executive leadership teams and senior management, as they make decisions on future investments in Sterile Fill-Finish to leverage attractive growth opportunities in this segment. The insights and analysis presented by Expert Insights are based upon extensive primary and secondary research, interviews conducted with our real-world experienced operating executives, subject matter experts and industry key opinion leaders, and a thorough review of industry reports and market data. To receive an immediate digital download of the report, or to view Sample Content, Companies, Technologies, Drug Modailties and Therapeutic Areas covered in the report: https://lnkd.in/eiTj_q8N Questions about the Report? Contact [email protected] #pharmaservices #PEInsights #privateequity #pharmaservices #PE #privateequityfunds #bio #dcat #bioevents #cdmo #Cpo #Cpos #cro #clinicalresearch #contractpackaging #drugdevelopment #bio #contractmanufacturing #investing #healthcareindustry #cphi #cphiphila #investmentbankers #investmentbanking #mergersandacquisitions #venturecapital #vc #vcfundng #privateequityfirms #privatecredit #privatedebt #investorrelations #DealCloud #financialservices #hedgefund #familyoffice #familyoffices #corporatedevelopment #duediligence #dd #sterilefillfinish #biologics #cellandgene #drugproduct #biomanufacturing

STATE OF THE STERILE FILL-FINISH MARKET 2024 REPORT. The most up to date data and analysis of markets, pipelines, trends and outsourcing details on the Sterile Fill-Finish Market, with exclusive insights from C-Level operating executives on context and implications. Published by Expert Insights, the World's Leading Advisory Services, Investment Research and Strategy Consulting Firm in Pharma Services. SAMPLE OF PHARMA & BIOTECHS COVERED AND MENTIONED: AbbVie, Amgen, AstraZeneca, Baxter International, Bayer AG, BioNTech, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, Endo Pharmaceutical, F. Hoffmann-La Roche, Gilead Sciences, GSK, Johnson and Johnson, Merck & Co, Moderna, Novartis, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceutical, Teva Pharmaceutical SAMPLE OF CDMOs COVERED AND MENTIONED: Aenova, AGC Biologics, Ajinomoto, Alcami, Almac, Argonaut Manufacturing Services, August Bioservices, Bora Pharma Co, Bushu Pharma, Carbogen Amcis, Catalent Pharma Solutions, Curia, Delpharm, Fareva, Fujifilm Diosynth, Grand River Aseptic Manufacturing, INCOG, Jubilant HollisterStier, Lifecore Biomedical, Lonza, National Resilience, Northway Biotech, PCI Pharma, Pii, Recipharm, Samsung Biologics, Selkirk Pharma, Sharp Packaging, Siegfried Holdings, Simtra BioPharma Solutions, Singota Solutions, ten23 Health, ThermoFisher Patheon, Vetter, Wuxi STA, And many others. The report will be invaluable to CDMO investors, dealmakers and market, strategy, sales, and Research & Development executives, including executive leadership teams and senior management, as they make decisions on future investments in Sterile Fill-Finish to leverage attractive growth opportunities in this segment. The insights and analysis presented by Expert Insights are based upon extensive primary and secondary research, interviews conducted with our real-world experienced operating executives, subject matter experts and industry key opinion leaders, and a thorough review of industry reports and market data. To receive an immediate digital download of the report, or to view Sample Content, Companies, Technologies, Drug Modailties and Therapeutic Areas covered in the report: https://lnkd.in/eiTj_q8N Questions about the Report? Contact [email protected] #privateequity

STATE OF THE STERILE FILL-FINISH MARKET 2024 REPORT. The most up to date data and analysis of markets, pipelines, trends and outsourcing details on the Sterile Fill-Finish Market, with exclusive insights from C-Level operating executives on context and implications. Published by Expert Insights, the World's Leading Advisory Services, Investment Research and Strategy Consulting Firm in Pharma Services. SAMPLE OF PHARMA & BIOTECHS COVERED AND MENTIONED: AbbVie, Amgen, AstraZeneca, Baxter International, Bayer AG, BioNTech, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, Endo Pharmaceutical, F. Hoffmann-La Roche, Gilead Sciences, GSK, Johnson and Johnson, Merck & Co, Moderna, Novartis, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceutical, Teva Pharmaceutical SAMPLE OF CDMOs COVERED AND MENTIONED: Aenova, AGC Biologics, Ajinomoto, Alcami, Almac, Argonaut Manufacturing Services, August Bioservices, Bora Pharma Co, Bushu Pharma, Carbogen Amcis, Catalent Pharma Solutions, Curia, Delpharm, Fareva, Fujifilm Diosynth, Grand River Aseptic Manufacturing, INCOG, Jubilant HollisterStier, Lifecore Biomedical, Lonza, National Resilience, Northway Biotech, PCI Pharma, Pii, Recipharm, Samsung Biologics, Selkirk Pharma, Sharp Packaging, Siegfried Holdings, Simtra BioPharma Solutions, Singota Solutions, ten23 Health, ThermoFisher Patheon, Vetter, Wuxi STA, And many others. The report will be invaluable to CDMO investors, dealmakers and market, strategy, sales, and Research & Development executives, including executive leadership teams and senior management, as they make decisions on future investments in Sterile Fill-Finish to leverage attractive growth opportunities in this segment. The insights and analysis presented by Expert Insights are based upon extensive primary and secondary research, interviews conducted with our real-world experienced operating executives, subject matter experts and industry key opinion leaders, and a thorough review of industry reports and market data. To receive an immediate digital download of the report, or to view Sample Content, Companies, Technologies, Drug Modailties and Therapeutic Areas covered in the report: https://lnkd.in/eiTj_q8N Questions about the Report? Contact [email protected] #drugdevelopment

STATE OF THE STERILE FILL-FINISH MARKET 2024 REPORT. The most up to date data and analysis of markets, pipelines, trends, outsourcing details, M&A and investments on the Sterile Fill-Finish Market, with exclusive insights from C-Level operating executives on context and implications. Published by Expert Insights, the World's Leading Advisory Services, Investment Research and Strategy Consulting Firm in Pharma Services. SAMPLE OF PHARMA & BIOTECHS COVERED AND MENTIONED: AbbVie, Amgen, AstraZeneca, Baxter International, Bayer AG, BioNTech, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, Endo Pharmaceutical, F. Hoffmann-La Roche, Gilead Sciences, GSK, Johnson and Johnson, Merck & Co, Moderna, Novartis, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceutical, Teva Pharmaceutical SAMPLE OF CDMOs COVERED AND MENTIONED: Aenova, AGC Biologics, Ajinomoto, Alcami, Almac, Argonaut Manufacturing Services, August Bioservices, Bora Pharma Co, Bushu Pharma, Carbogen Amcis, Catalent Pharma Solutions, Curia, Delpharm, Fareva, Fujifilm Diosynth, Grand River Aseptic Manufacturing, INCOG, Jubilant HollisterStier, Lifecore Biomedical, Lonza, National Resilience, Northway Biotech, PCI Pharma, Pii, Recipharm, Samsung Biologics, Selkirk Pharma, Sharp Packaging, Siegfried Holdings, Simtra BioPharma Solutions, Singota Solutions, ten23 Health, ThermoFisher Patheon, Vetter, Wuxi STA, And many others. The report will be invaluable to CDMO investors, dealmakers and market, strategy, sales, and Research & Development executives, including executive leadership teams and senior management, as they make decisions on future investments in Sterile Fill-Finish to leverage attractive growth opportunities in this segment. The insights and analysis presented by Expert Insights are based upon extensive primary and secondary research, interviews conducted with our real-world experienced operating executives, subject matter experts and industry key opinion leaders, and a thorough review of industry reports and market data. To receive an immediate digital download of the report, or to view Sample Content, Companies, Technologies, Drug Modailties and Therapeutic Areas covered in the report: https://lnkd.in/eiTj_q8N Questions about the Report? Contact [email protected] #clinicalresearch

The NC pharmaceutical industry #growth and #innovation has been nothing but astonishing since I moved here. While this is not a comprehensive list, I wanted to highlight some of the major expansions and builds in just the last few years for my friends who may have missed them (Note: Some information in this post may be out of date - information sourced from Fierce Pharma and respective company websites). Novo Nordisk: $𝟐𝐁 investment to build an Active Pharmaceutical Ingredient (API) facility. This facility aimed to increase production capacity for diabetes treatments. + Novo Nordisk: Additional $𝟒.𝟏𝐁 investment to build a second fill-finish manufacturing plant, doubling the combined footprint of Novo Nordisk's existing facilities in the state (~3,500 𝑗𝑜𝑏𝑠 𝑖𝑛 𝑁𝐶 𝑡𝑜𝑡𝑎𝑙). Eli Lilly and Company: over $𝟏𝐁 investment in a new injectable product and device manufacturing facility in Concord, North Carolina. (~600 𝑛𝑒𝑤 𝑗𝑜𝑏𝑠). + Eli Lilly and Company: $𝟒𝟓𝟎𝐌 investment in its manufacturing site in Research Triangle Park (~100 𝑛𝑒𝑤 𝑗𝑜𝑏𝑠). FUJIFILM Diosynth Biotechnologies: $𝟏.𝟐𝐁 in expansion of its end-to-end biomanufacturing facility in Holly Springs. This brought the total investment in the plant to more than $𝟑.𝟐𝐁 (~680 𝑛𝑒𝑤 𝑗𝑜𝑏𝑠). Amgen: $𝟓𝟓𝟎𝐌 investment in a greenfield manufacturing facility in Holly Springs for biologics and other medicine production. Resilience: $𝟐𝟐𝟓𝐌 aimed at scaling up production capacity. SCHOTT Pharma: $𝟑𝟕𝟏𝐌 in a new prefilled syringe manufacturing facility in Wilson, North Carolina (~400 𝑛𝑒𝑤 𝑗𝑜𝑏𝑠). Fresenius Kabi: $𝟏𝟎𝟎𝐌 expansion of its pharmaceutical manufacturing facility in Wilson, increasing production capacity for generic drugs in prefilled syringes (~450 𝑛𝑒𝑤 𝑗𝑜𝑏𝑠). Pfizer: $𝟔𝟎𝟎𝐌 investment in expanding its gene therapy manufacturing facility at its Sanford campus to improve clinical and commercial-scale manufacturing capabilities. Kyowa Kirin International plc. Kirin: $𝟓𝟑𝟎𝐌 to establish a biologics manufacturing facility in Sanford (~100 𝑛𝑒𝑤 𝑗𝑜𝑏𝑠). These significant investments in North Carolina foreshadow its growing role as a hub for biotech manufacturing and innovation. I'm glad I get to be a part of it, and I'm equally excited to see what comes next! #NC #Biotech #PharmaceuticalManufacturing

Evolution of Top Pharma companies since 2009

Interesting to see the evolution of the overall market and the dynamics of individual players

𝐄𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐨𝐟 𝐓𝐨𝐩 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐛𝐲 𝐑𝐞𝐯𝐞𝐧𝐮𝐞    I previously wrote about the evolution of top #medtech companies by revenue. Here is a look at the evolution of the top #pharmaceutical and #biotech companies over the last 15 years. Today, the following are top #biopharma companies by #revenue: 1-   Johnson & Johnson$85B 2-   Sinopharm $82B 3-   Roche $67B 4-   Merck $60B 5-   Pfizer $58B 6-   AbbVie $54B 7-   Bayer $52B 8-   Sanofi $50B 9-   Novartis $47B 10- AstraZeneca $46B 11- Bristol Myers Squibb $45B 12- GSK $38B 13- Eli Lilly and Company $34B 14- Novo Nordisk $34B 15- Takeda $30B 16- Amgen $28B 17- Boehringer Ingelheim $28B 18- Gilead Sciences $27B 19- Merck Group $23B Some of the trends are interesting to watch. The total market has grown from $600 billion in 2009 to $1.1 trillion in 2023, reflecting over 80% growth, or a 5% compound annual growth rate. Over the years the top players have largely remained consistent, while Sinopharm has gradually emerged as one of the largest pharmaceutical companies. The impact of #COVID on the revenues of some of the key players is also evident. During COVID, Pfizer's revenue surged to $80B and $100B in 2021 and 2022, making it the biggest pharmaceutical company in the world. A position that Pfizer could not maintain in 2023. Moderna and BioNTech went through a similar trend. Before COVID, both companies had less than $1B in revenue. During COVID both companies joined the top pharmaceutical companies by revenue. A position that they could not maintain in 2023. It would be interesting to see how these rankings evolve in the coming years. I must add that it is not very common to compare the revenue of pharma and biotech companies as most of these companies have very different products, in very different markets, often complementary. To gain a deeper understanding of each of these companies, one must dive into their strategy, business model, product portfolio, global operations, and overall financial and economics. * For all the companies, I am reporting the total revenue which may include revenue from their medical or other diagnostics divisions. Views and ideas are my own. The content that I provide here is public data and intended to be educational only and is not endorsement or financial advice. I always encourage the readers to do their own research. Music: We Have a Dream – Joey Richmond Visualizer: Flourish Sources: MacroTrends, Statista, Individual company filings, others

𝐄𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐨𝐟 𝐓𝐨𝐩 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐛𝐲 𝐑𝐞𝐯𝐞𝐧𝐮𝐞    I previously wrote about the evolution of top #medtech companies by revenue. Here is the look at the evolution of the top #pharmaceutical and #biotech companies over the last 15 years. Today, the following are top #biopharma companies by #revenue: 1-   Johnson & Johnson$85B 2-   Sinopharm $82B 3-   Roche $67B 4-   Merck $60B 5-   Pfizer $58B 6-   AbbVie $54B 7-   Bayer $52B 8-   Sanofi $50B 9-   Novartis $47B 10- AstraZeneca $46B 11- Bristol Myers Squibb $45B 12- GSK $38B 13- Eli Lilly and Company $34B 14- Novo Nordisk $34B 15- Takeda $30B 16- Amgen $28B 17- Boehringer Ingelheim $28B 18- Gilead Sciences $27B 19- Merck Group $23B Some of the trends are interesting to watch. The total market has grown from $600 billion in 2009 to $1.1 trillion in 2023, reflecting over 80% growth, or a 5% compound annual growth rate. Over the years the top players have largely remained consistent, while Sinopharm has gradually emerged as one of the largest pharmaceutical companies. The impact of #COVID on the revenues of some of the key players is also evident. During COVID, Pfizer revenue surged to $80B and $100B in 2021 and 2022, making it the biggest pharmaceutical company in the world. A position that Pfizer could not maintain in 2023. Moderna and BioNTech went through a similar trend. Prior to COVID both companies had less than $1B in revenue. During COVID both companies joined the top pharmaceutical companies by revenue. A position that they could not maintain in 2023. It would be interesting to see how these rankings evolve in the coming years. I must add that it is not very common to compare the revenue of pharma and biotech companies as most of these companies have very different products, in very different markets, often complementary. To gain a deeper understanding of each of these companies, one must dive into their strategy, business model, product portfolio, global operations, and their overall financial and economics. * For all the companies, I am reporting the total revenue which may include revenue from their medical or other diagnostics divisions. Views and ideas are my own. The content that I provide here are public data and intended to be educational only and are not endorsement or financial advice. I always encourage the readers to do their own research. Music: We have a Dream – Joey Richmond Visualizer: Flourish Sources: MacroTrends, Statista, Individual company filings, others

Visual representation of the revenue evolution of the top #pharmaceutical and #biotech companies over the last 15 years.